<SEC-DOCUMENT>0001269026-15-000062.txt : 20151105
<SEC-HEADER>0001269026-15-000062.hdr.sgml : 20151105
<ACCEPTANCE-DATETIME>20151105085934
ACCESSION NUMBER:		0001269026-15-000062
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151105
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151105
DATE AS OF CHANGE:		20151105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDICA Corp
		CENTRAL INDEX KEY:			0001269026
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33624
		FILM NUMBER:		151199011

	BUSINESS ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119
		BUSINESS PHONE:		801-839-3516

	MAIL ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMEDICA CORP
		DATE OF NAME CHANGE:	20031104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a20151105_8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>8-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s77f0fc0e2b494cd792c7b7f3be6e7b08"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported): November 5, 2015</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Amedica Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="32%"></td><td width="2%"></td><td width="32%"></td><td width="2%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-33624</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84-1375299</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1885 West 2100 South</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Salt Lake City, UT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84119</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801) 839-3500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s77f0fc0e2b494cd792c7b7f3be6e7b08"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 5, 2015, the Registrant issued a press release announcing that it has entered into a multi-year private label agreement with a regional medical device company that markets solutions for the treatment of spinal disorders.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">November 5, 2015.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20151105_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sf3a4347cb0394ecc80450a3df01c5fd6"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="amedica.gif" style="font-size:14pt;font-weight:bold;height:89px;width:165px;"></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Amedica Corporation Signs Additional Silicon Nitride Private Label Agreement </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Newest Alliance to Positively Impact Future Financial Results</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SALT LAKE CITY,&#160;November 5, 2015 -&#160;Amedica Corporation&#160;(Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce it has entered into a multi-year private label agreement with a regional medical device company that markets solutions for the treatment of spinal disorders.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the terms of the non-exclusive agreement, Amedica will provide sterile-packed silicon nitride spinal interbody fusion devices to be available in key domestic markets. The agreement underscores Amedica&#8217;s continued focus to provide superior and innovative solutions to the market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;We are very pleased to announce an additional private label partner,&#8221; said Dr. Sonny Bal, chairman and CEO of&#160;Amedica Corporation. &#8220;This newest alliance should positively impact our financial results and further validates our uniquely differentiated biomaterial technology, while complementing our current distribution structure. We remain committed to offering our partners a biomaterial with inherent distinct benefits to improve the efficacy of spinal fusion procedures, resulting in enhanced patient care.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amedica's spinal interbody fusion devices are made of a micro-composite silicon nitride biomaterial - a breakthrough ceramic containing the world&#8217;s first natural nano-surface biotechnology. This unique biomaterial is also hydrophilic to attract both osteoblasts and physiologic proteins to ensure reliable osteointegration, and its surface biochemistry inhibits bacterial biofilm adhesion. This combination of optimal material properties is unique to Amedica's silicon nitride material platform.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About&#160;Amedica Corporation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing private label and OEM partnerships.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For more information </font><font style="font-family:inherit;font-size:11pt;">on Amedica or its silicon nitride material platform, please visit&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.amedica.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of Amedica and members of its management team that this new alliance should positively impact its financial results and other statements with respect to Amedica's future business operations and acceptance of its technology platform.  Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sf3a4347cb0394ecc80450a3df01c5fd6"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contact:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mike Houston</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VP, Commercialization </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">801-839-3534</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">IR@amedica.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Robert Haag</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IRTH Communications</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">866-976-4784</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">amda@irthcommunications.com</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>amedica.gif
<TEXT>
begin 644 amedica.gif
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M^O?X\?7Y^_GV\?WZ\_[^_B'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MY HX^<FVM0B($0((!6C PQ(QL46P2V"6T&$!$2BF?!'0VM-$80 7H"<Z-&"
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MP# (DZ!+OK"'95 $IA<%=_ .WE $>D (;9 %SX &8: -97 "RA *4B -_WZ
M"" Y!L_P!EO@C*7'"P-Q#W^ ".$0F=G0"85P"BOP",$@!9/@#5G@"\$PE-!P
M!F+ #?.0#Y]0!+I@#+T@C5:I HCP#'N0!=L@!U? #,VP!V&P#&80!KV@"]$0
M#FGP!=%YA3/@"-\  X@ #7]P!=10BJJ F(- !8B #L' "(2P"VLXA'QX!8!P
M!B 0!O;X"7YH5,FY!XAPB(;P#]]0!;QPF<B !)&8"E?P#$_@ 5^PAA=)![I
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3[-N^[ON^\!N_\CN_]%M  0$ .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
